420 related articles for article (PubMed ID: 32050434)
1. Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant
Vena A; Giacobbe DR; Castaldo N; Cattelan A; Mussini C; Luzzati R; Rosa FG; Del Puente F; Mastroianni CM; Cascio A; Carbonara S; Capone A; Boni S; Sepulcri C; Meschiari M; Raumer F; Oliva A; Corcione S; Bassetti M
Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32050434
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
4. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S; Wang H; Feng S
Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and
Zalas-Więcek P; Prażyńska M; Pojnar Ł; Pałka A; Żabicka D; Orczykowska-Kotyna M; Polak A; Możejko-Pastewka B; Głowacka EA; Pieniążek I; Pawlik M; Grys M; Bogiel M
Infect Drug Resist; 2022; 15():1289-1304. PubMed ID: 35370409
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study.
Cultrera R; Libanore M; Barozzi A; d'Anchera E; Romanini L; Fabbian F; De Motoli F; Quarta B; Stefanati A; Bolognesi N; Gabutti G
Antibiotics (Basel); 2020 Sep; 9(10):. PubMed ID: 32987821
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
8. Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing
Isler B; Ezure Y; Romero JLG; Harris P; Stewart AG; Paterson DL
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046493
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review.
Soriano A; Carmeli Y; Omrani AS; Moore LSP; Tawadrous M; Irani P
Infect Dis Ther; 2021 Dec; 10(4):1989-2034. PubMed ID: 34379310
[TBL] [Abstract][Full Text] [Related]
12. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
Shields RK; Nguyen MH; Chen L; Press EG; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507064
[TBL] [Abstract][Full Text] [Related]
13. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
[TBL] [Abstract][Full Text] [Related]
14. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis.
Onorato L; Di Caprio G; Signoriello S; Coppola N
Int J Antimicrob Agents; 2019 Dec; 54(6):735-740. PubMed ID: 31479738
[TBL] [Abstract][Full Text] [Related]
16. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.
Lagacé-Wiens P; Walkty A; Karlowsky JA
Core Evid; 2014; 9():13-25. PubMed ID: 24493994
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
20. Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study.
Meng H; Zhao Y; An Q; Zhu B; Cao Z; Lu J
Infect Drug Resist; 2023; 16():5815-5824. PubMed ID: 37692471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
